SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer

Официальное название

SHR-1701 in Combination With Radiotherapy and Chemotherapy as Perioperative Treatment for Resectable Locally Advanced Rectal Cancer, an Open Label, Single-arm, Multicenter Phase II Trial

Обзор

This study will evaluate the efficacy and safety of SHR-1701 combined with radiotherapy and chemotherapy as perioperative treatment for locally advanced rectal cancer. Eligible patients will receive standard chemoradiation with SHR-1701 followed by XELOX combined with SHR-1701. In all subjects, restaging pelvic MRI with chest and abdominal CT will be performed after completion of neoadjuvant treatment to determine resectability and to rule out any evidence of metastases. Subjects who have resectable disease will undergo surgery. Adjuvant XELOX combined with SHR-1701 will be given after surgery.

Вмешательства

• Препарат SHR-1701；Capecitabine；Oxaliplatin
  Radiation: Radiation therapy 50.4Gy in 28 fractions to the pelvis on Days 1-5 every week. Drug: Capecitabine Capecitabine 825mg/m\^2 orally twice daily (bid) 5 days/week during radiotherapy. Drug:SHR-1701 Drug: Capecitabine (XELOX) Capecitabine 1000mg/m\^2 orally twice daily (bid) day1-day14, q3w. Drug: Oxaliplatin Oxaliplatin 130mg/m\^2, day1, iv, q3w

Первичные конечные точки

• Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0 [Срок оценки: At week 16, DAY1]
• Percentage of participants with Pathological complete response ( pCR ) [Срок оценки: At week 16, DAY1]

Вторичные конечные точки (6)

• Tumor regression grade ( TRG ) [Срок оценки: At week 16, DAY1]
• Percentage of participants with R0 Resection ( R0 ) [Срок оценки: At week 16, DAY1]
• Percentage of participants with Clinical complete response ( cCR ) rate. [Срок оценки: At week 16, DAY1]
• Event-free survival ( EFS ) [Срок оценки: Year 1, Year 2, Year 3]
• Overall survival ( OS ) [Срок оценки: Year 1, Year 2, Year 3]
• Disease-free survival ( DFS ) [Срок оценки: Year 1, Year 2, Year 3]

Критерии участия

Критерии включения

• Be willing and able to provide written informed consent for the trial.
• Locally advanced rectal adenocarcinoma and was evaluated as resectable ;
• The inferior margin of the tumor ≤ 10 cm from the anal verge ;
• No prior anti-cancer treatment for rectal cancer;
• Estern Cooperative Oncology Group (ECOG) Performance status (PS) of 0 or 1;
• Adequate hematologic and end-organ function;
• Contraception was initiated from the signing of the informed consent until at least 6 months after the last dosing of the study drug

Критерии исключения

• Unresectable disease determined by investigators
• Recurrent rectal cancer
• Evidence of metastatic disease or lateral lymph node metastases
• Presence of synchronous colorectal cancer
• Presence of obstruction or imminent obstruction
• Not eligible for long-course radiotherapy
• Severe cardiovascular and cerebrovascular diseases;Have clinical heart symptoms or diseases that are not well controlled
• Prior malignancy within the prior 5 years. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical/breast cancer.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Китай · 1 центр

• Fudan University Zhongshan Hospital — Шанхай

Публикации

• Tang W, Lv Y, Xie H, Wei Y, Wang J, Yu M, Jiang Y, Mao R, Huang C, Rao S, Ding K, Chang W, He G, Xu J. Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer. Cancer Lett. 2026 Jan 1;636:218006. doi: 10.1016/j.canlet.2025.218006. Epub 2025 Aug 26. PMID 40876501

Идентификаторы

NCT: NCT05300269 · SHR-1701-II-213

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗